Artificial intelligence–assisted urine cytology based on the Paris System for Reporting Urothelial Carcinoma
Cancer Cytopathology · 2026-06 · 134 (6)
DOI: 10.1002/cncy.70120 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Cytopathology, online erschienen am 01.06.2026. Verfasst von Lan Chen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beij…. Hauptthemen laut MEDLINE: Artificial Intelligence, Cytodiagnosis, Urologic Neoplasms, Carcinoma, Transitional Cell. Die Arbeit nennt 38 Literaturangaben. Gefördert von: National High Level Hospital Clinical Research Funding, Bethune·Urinary Tumor Special Research Fund Project.
Abstract (Originalsprache)
Background
Urine cytology is a noninvasive and valuable tool for detecting urothelial carcinoma but suffers from variable sensitivity and observer dependency. Artificial intelligence (AI) may enhance the diagnostic accuracy and efficiency of urine cytology. The objective of this study was to develop and validate an AI‐based cytology system for urothelial carcinoma detection in both clinical and screening contexts.
Methods
In total, 328 retrospective clinical cases and 1489 prospective health screening samples were analyzed. All specimens underwent liquid‐based cytology and were digitized at ×20 magnification. For model development, ed 269 annotated training slides (56,710 cells) were used. The AI pipeline mimicked cytopathologist workflow, integrating deep learning–based cell detection and segmentation with feature extraction and support vector machine classification into AI‐negative, AI‐atypical, and AI‐positive categories according to The Paris System for Reporting the Urinary Cytology. Agreement was assessed using weighted κ values and prevalence‐adjusted, bias‐adjusted κ values.
Results
In the clinical cohort, AI achieved 83.0% agreement with histopathology and 82.6% agreement with expert cytology. Weighted κ values (κ, 0.631–0.661) reflected substantial agreement, with discrepancies mainly between adjacent categories. In the health screening cohort, the prevalence‐adjusted, bias‐adjusted κ was 0.647 despite low prevalence. AI demonstrated a high negative predictive value of 99.7% and negative percent agreement of 82.3%, with a minimal false‐omission rate (0.25%).
Conclusions
AI‐assisted urine cytology exhibited substantial concordance with expert interpretation and histopathologic standards. Its capability of screen‐out and high negative predictive value support its potential as a reliable triage tool, improving workflow efficiency while maintaining diagnostic reliability in large‐scale screening.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pathology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China.
- Department of Medical Development, Hangzhou Zhiwei Information Technology Co., Ltd., Hangzhou, China.
Förderung
- National High Level Hospital Clinical Research Funding
- Bethune·Urinary Tumor Special Research Fund Project
Zitieren
APA
Chen, L., Cao, X., Lu, Z., Liu, L., Sun, M., Wu, Y., & Zhang, W. (2026). Artificial intelligence–assisted urine cytology based on the Paris System for Reporting Urothelial Carcinoma. Cancer Cytopathology, 134(6). https://doi.org/10.1002/cncy.70120
Vancouver
Chen L, Cao X, Lu Z, Liu L, Sun M, Wu Y, et al. Artificial intelligence–assisted urine cytology based on the Paris System for Reporting Urothelial Carcinoma. Cancer Cytopathology. 2026;134(6). doi:10.1002/cncy.70120
BibTeX
@article{Chen2026,
author = {Chen, Lan and Cao, Xinyi and Lu, Zongyue and Liu, Longteng and Sun, Mingjun and Wu, Yulong and Zhang, Wei},
title = {Artificial intelligence–assisted urine cytology based on the Paris System for Reporting Urothelial Carcinoma},
journal = {Cancer Cytopathology},
year = {2026},
volume = {134},
number = {6},
doi = {10.1002/cncy.70120}
}
EUVIMED